Shareholder Boar
Biotech, special situations, event-driven, deep value

Chelsea Therapeutics Deal Terms: Be Careful

On May 7, 2014, Chelsea Therapeutics (NASDAQ:CHTP) agree to be acquired by the Danish corporation H. Lundbeck A/S (OTCPK:HLUYY). The acquisition is structured as a tender offer followed by a second step merger. The tender offer has already started and is scheduled to close June 20, 2014.

Tendering shareholders are to receive $6.44 in cash plus one Contingent Value Right (NYSEMKT:CVR) per share. Shareholders who do not tender will receive the same consideration after the merger is completed.

A source of some confusion is the structure of the CVR. Issuance of CVRs in pharmaceutical buyouts has become common place in recent years. These rights are commonly tied to the performance of key assets of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details